19113-Breast Cancer-NA-126

Breast Cancer

EPIK-B2: A two part, Phase III, multicenter, randomized (1:1), double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with trastuzumab and pertuzumab as maintenance therapy in patients with HER2-positive advanced breast cancer with a PIK3CA mutation (CBYL719G12301)

  • Details

ClinicalTrials.gov ID: NCT04208178
Diagnosis Type: NA
USOR Number:

  • Address

4700 E Hale Parkway, Suite 400
Denver, CO 80220
P: (303) 321-0302

Search by practice name, trial titles, indicators and specific disease types.